No Data
Bede Pharmaceutical (688073) Third Quarter Report Review 2024: Overseas markets continue to exert strength, and the operation is steadily improving.
Subject: The company releases the third quarter report for 2024. In the first three quarters of 2024, the company's revenue was 0.811 billion yuan, a year-on-year increase of 0.79%, net income attributable to the mother was 0.084 billion yuan, a year-on-year decrease of 26.05%, and non-net income was 0.
Bide Pharmaceutical (688073): Profitability continues to improve with steady revenue growth.
Event: In the first three quarters of 2024, revenue reached 0.811 billion yuan (+0.79% year-on-year), net income attributable to parent company was 83.8539 million yuan (-26.05% year-on-year), non-net income attributable to parent company was 72.3904 million yuan.
Bide Pharmaceutical (688073): Structural adjustment, obvious elasticity, moving out of the low point of profitability.
Investment Highlights Performance: Revenue growth rate slowed down, profit growth rate rebounded in 2024Q1-3, achieving revenue of 0.811 billion yuan, yoy +0.79%; achieving net income attributable to parent company of 0.084 billion yuan, yoy -26.05%.
Bide Pharmaceuticals: third quarter report 2024
Third Quarter Report 2024
Bede Pharmaceuticals (688073.SH) released its performance for the first three quarters, with a net income of 83.85 million yuan, a year-on-year decrease of 26.05%.
Bide Pharmaceutical (688073.SH) disclosed its third quarter report for 2024. During the reporting period, the company achieved revenue of 8.1...
No Data
No Data